Join us at ASTRO to learn more about proton therapy. Registration link go.iba-worldwide.com/IBAatASTRO2023 #ASTRO2023 #proton

"I see many of you may be immigrants, just like I am, its a little bit more difficult, but we are more resilient - that's the same for the women" Katalin Kariko what an inspiration to all the women immigrant scientist!

For stage III NSCLC patients, adjuvant durvalumab is critical. With protons 22% more patients are likely able to recieve this treatment. Proton and photon radiotherapy in stage III NSCLC: effects on hematological toxicity and adjuvant immune therapy thegreenjournal.com/article/S0167-…

EDIC-Effective Dose to Immune Cells can predict lymphopenia and survival. Proton therapy leads to lower EDIC doses than photons.

Ultrahigh dose rates could reduce the level of immune cell depletion during #protontherapy of brain cancer. ow.ly/wf1i50QvRKl

New article (Vol 193) Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam RT for patients with inoperable locally advanced NSCL carcinoma Kelsey L. Corrigan et al. doi.org/10.1016/j.rado… thegreenjournal.com/article/S0167-…

A major landmark paper for FLASH. After showing normal tissue protection, we show impact in radioresistance context. Congratulation to the team, congratulation Ron and all the best for your new start in Belgium. Ron Leavitt Aymeric Almeida Pierre Montay-Gruel 💙💛 Benoît Petit

Want to learn more about ConformalFLASH? Please join us for this very exciting seminar highlighting the technological advancements which helps bring together the physical advantages of proton Bragg peak with the biological sparing effect of FLASH RT! linkedin.com/posts/iba-prot…

Out now! Simultaneous publication with #AACR24 poster: "Proton FLASH radiotherapy ameliorates radiation-induced salivary gland dysfunction and oral mucositis and increases survival in a mouse model of head and neck cancer" Chowdhury et al. bit.ly/49pWo12 AACR

Late Toxicity of Prostate Ultrahypofractionated Radiation Therapy Compared With Moderate Hypofractionation in a Randomized Trial - International Journal of Radiation Oncology, Biology, Physics redjournal.org/article/S0360-…

FLASH Radiotherapy: What Can FLASH's Ultra High Dose Rate Offer to the Treatment of Patients With Sarcoma? - ScienceDirect ⁦Eric Diffenderfer, Ph.D.⁩ ⁦Michele Kim⁩ ⁦@costas_koumenis⁩ sciencedirect.com/science/articl…

Improvement in survival and reduction in lung fibrosis after proton minibeam irradiation in mice! sciencedirect.com/science/articl…

IBA has signed a contract with the Connecticut Proton Therapy Center, a collaboration between Yale New Haven Health, Hartford HealthCare and Proton International, for the installation of a Proteus®ONE compact proton therapy system.

Hot off the press - ASCO H+N abstracts - quick look at amazing Ph3 RCT of proton vs photon for oropharynx cancer IMPT with non-inf PFS (HR 0.87) w/significantly less PEG and less wt loss Can't wait to see the pres for details but is this new SoC? meetings.asco.org/abstracts-pres…

Congratulations to all participating institutions for driving Phase III Level I evidence for proton therapy in head and neck malignancies to be presented ASCO on June 4th. meetings.asco.org/abstracts-pres… MD Anderson Cancer Center National Association for Proton Therapy ASTRO

I think one of the best #radonc inventions this century

ft. H. Ni, W. Zou, N. Akhtar, Ritama Paul, PhD, M. Huang, D. Zhang, H. Zheng, R. Zhang, R. Ma, G. Ngo, Eric Diffenderfer, Ph.D., S. Motlagh, Michele Kim, Andy Minn, J. Dorsey, J. Metz, C. Koumenis, Y. Gong, Y. Fan, L. Zhang & Jessica Foster Penn Radiation Oncology Residency nature.com/articles/s4301…

Practice-changing data from Dr. Steven Frank Steven J. Frank, MD at #PTCOG63 on head & neck proton therapy. Level 1 evidence shows improved survival, reduced G-tube dependence, and favorable cost-effectiveness vs IMRT. A new standard is taking shape. The Particle Therapy Co-Operative Group (PTCOG) MD Anderson Cancer Center

First phase III randomized study showed an improvement in overall survival with proton-based IMPT compared to photon IMRT in head and neck cancer. This was presented today during the The Particle Therapy Co-Operative Group (PTCOG) plenary session by Steven J. Frank, MD. The exciting data provides justification for IMPT.